Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC)

New insights on the role of phosphatydil-inositol-3 kinase

Marianna Scrima, Carmela de Marco, Fernanda Fabiani, Renato Franco, Giuseppe Pirozzi, Gaetano Rocco, Maria Ravo, Alessandro Weisz, Pietro Zoppoli, Michele Ceccarelli, Gerardo Botti, Donatella Malanga, Giuseppe Viglietto

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Aberrant activation of PI3K/AKT signalling represents one of the most common molecular alterations in lung cancer, though the relative contribution of the single components of the cascade to the NSCLC development is still poorly defined. In this manuscript we have investigated the relationship between expression and genetic alterations of the components of the PI3K/AKT pathway [KRAS, the catalytic subunit of PI3K (p110α), PTEN, AKT1 and AKT2] and the activation of AKT in 107 surgically resected NSCLCs and have analyzed the existing relationships with clinico-pathologic features. Expression analysis was performed by immunohistochemistry on Tissue Micro Arrays (TMA); mutation analysis was performed by DNA sequencing; copy number variation was determined by FISH. We report that activation of PI3K/AKT pathway in Italian NSCLC patients is associated with high grade (G3-G4 compared with G1-G2; n = 83; p<0.05) and more advanced disease (TNM stage III vs. stages I and II; n = 26; p<0.05). In addition, we found that PTEN loss (41/104, 39%) and the overexpression of p110α (27/92, 29%) represent the most frequent aberration observed in NSCLCs. Less frequent molecular lesions comprised the overexpression of AKT2 (18/83, 22%) or AKT1 (17/96, 18%), and KRAS mutation (7/63, 11%). Our results indicate that, among all genes, only p110α overexpression was significantly associated to AKT activation in NSCLCs (p = 0.02). Manipulation of p110α expression in lung cancer cells carrying an active PI3K allele (NCI-H460) efficiently reduced proliferation of NSCLC cells in vitro and tumour growth in vivo. Finally, RNA profiling of lung epithelial cells (BEAS-2B) expressing a mutant allele of PIK3 (E545K) identified a network of transcription factors such as MYC, FOS and HMGA1, not previously recognised to be associated with aberrant PI3K signalling in lung cancer.

Original languageEnglish
Article numbere30427
JournalPLoS One
Volume7
Issue number2
DOIs
Publication statusPublished - 17 Feb 2012
Externally publishedYes

Fingerprint

phosphatidylinositol 3-kinase
Inositol
lung neoplasms
Phosphatidylinositol 3-Kinases
Non-Small Cell Lung Carcinoma
phosphotransferases (kinases)
Phosphotransferases
Chemical activation
Cells
Lung Neoplasms
cells
Alleles
alleles
mutation
Mutation
protein subunits
Aberrations
DNA Sequence Analysis
lesions (animal)
immunohistochemistry

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC) : New insights on the role of phosphatydil-inositol-3 kinase. / Scrima, Marianna; de Marco, Carmela; Fabiani, Fernanda; Franco, Renato; Pirozzi, Giuseppe; Rocco, Gaetano; Ravo, Maria; Weisz, Alessandro; Zoppoli, Pietro; Ceccarelli, Michele; Botti, Gerardo; Malanga, Donatella; Viglietto, Giuseppe.

In: PLoS One, Vol. 7, No. 2, e30427, 17.02.2012.

Research output: Contribution to journalArticle

Scrima, M, de Marco, C, Fabiani, F, Franco, R, Pirozzi, G, Rocco, G, Ravo, M, Weisz, A, Zoppoli, P, Ceccarelli, M, Botti, G, Malanga, D & Viglietto, G 2012, 'Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): New insights on the role of phosphatydil-inositol-3 kinase', PLoS One, vol. 7, no. 2, e30427. https://doi.org/10.1371/journal.pone.0030427
Scrima, Marianna ; de Marco, Carmela ; Fabiani, Fernanda ; Franco, Renato ; Pirozzi, Giuseppe ; Rocco, Gaetano ; Ravo, Maria ; Weisz, Alessandro ; Zoppoli, Pietro ; Ceccarelli, Michele ; Botti, Gerardo ; Malanga, Donatella ; Viglietto, Giuseppe. / Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC) : New insights on the role of phosphatydil-inositol-3 kinase. In: PLoS One. 2012 ; Vol. 7, No. 2.
@article{718bd19b82e545e3939fccb0bafffc51,
title = "Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): New insights on the role of phosphatydil-inositol-3 kinase",
abstract = "Aberrant activation of PI3K/AKT signalling represents one of the most common molecular alterations in lung cancer, though the relative contribution of the single components of the cascade to the NSCLC development is still poorly defined. In this manuscript we have investigated the relationship between expression and genetic alterations of the components of the PI3K/AKT pathway [KRAS, the catalytic subunit of PI3K (p110α), PTEN, AKT1 and AKT2] and the activation of AKT in 107 surgically resected NSCLCs and have analyzed the existing relationships with clinico-pathologic features. Expression analysis was performed by immunohistochemistry on Tissue Micro Arrays (TMA); mutation analysis was performed by DNA sequencing; copy number variation was determined by FISH. We report that activation of PI3K/AKT pathway in Italian NSCLC patients is associated with high grade (G3-G4 compared with G1-G2; n = 83; p<0.05) and more advanced disease (TNM stage III vs. stages I and II; n = 26; p<0.05). In addition, we found that PTEN loss (41/104, 39{\%}) and the overexpression of p110α (27/92, 29{\%}) represent the most frequent aberration observed in NSCLCs. Less frequent molecular lesions comprised the overexpression of AKT2 (18/83, 22{\%}) or AKT1 (17/96, 18{\%}), and KRAS mutation (7/63, 11{\%}). Our results indicate that, among all genes, only p110α overexpression was significantly associated to AKT activation in NSCLCs (p = 0.02). Manipulation of p110α expression in lung cancer cells carrying an active PI3K allele (NCI-H460) efficiently reduced proliferation of NSCLC cells in vitro and tumour growth in vivo. Finally, RNA profiling of lung epithelial cells (BEAS-2B) expressing a mutant allele of PIK3 (E545K) identified a network of transcription factors such as MYC, FOS and HMGA1, not previously recognised to be associated with aberrant PI3K signalling in lung cancer.",
author = "Marianna Scrima and {de Marco}, Carmela and Fernanda Fabiani and Renato Franco and Giuseppe Pirozzi and Gaetano Rocco and Maria Ravo and Alessandro Weisz and Pietro Zoppoli and Michele Ceccarelli and Gerardo Botti and Donatella Malanga and Giuseppe Viglietto",
year = "2012",
month = "2",
day = "17",
doi = "10.1371/journal.pone.0030427",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC)

T2 - New insights on the role of phosphatydil-inositol-3 kinase

AU - Scrima, Marianna

AU - de Marco, Carmela

AU - Fabiani, Fernanda

AU - Franco, Renato

AU - Pirozzi, Giuseppe

AU - Rocco, Gaetano

AU - Ravo, Maria

AU - Weisz, Alessandro

AU - Zoppoli, Pietro

AU - Ceccarelli, Michele

AU - Botti, Gerardo

AU - Malanga, Donatella

AU - Viglietto, Giuseppe

PY - 2012/2/17

Y1 - 2012/2/17

N2 - Aberrant activation of PI3K/AKT signalling represents one of the most common molecular alterations in lung cancer, though the relative contribution of the single components of the cascade to the NSCLC development is still poorly defined. In this manuscript we have investigated the relationship between expression and genetic alterations of the components of the PI3K/AKT pathway [KRAS, the catalytic subunit of PI3K (p110α), PTEN, AKT1 and AKT2] and the activation of AKT in 107 surgically resected NSCLCs and have analyzed the existing relationships with clinico-pathologic features. Expression analysis was performed by immunohistochemistry on Tissue Micro Arrays (TMA); mutation analysis was performed by DNA sequencing; copy number variation was determined by FISH. We report that activation of PI3K/AKT pathway in Italian NSCLC patients is associated with high grade (G3-G4 compared with G1-G2; n = 83; p<0.05) and more advanced disease (TNM stage III vs. stages I and II; n = 26; p<0.05). In addition, we found that PTEN loss (41/104, 39%) and the overexpression of p110α (27/92, 29%) represent the most frequent aberration observed in NSCLCs. Less frequent molecular lesions comprised the overexpression of AKT2 (18/83, 22%) or AKT1 (17/96, 18%), and KRAS mutation (7/63, 11%). Our results indicate that, among all genes, only p110α overexpression was significantly associated to AKT activation in NSCLCs (p = 0.02). Manipulation of p110α expression in lung cancer cells carrying an active PI3K allele (NCI-H460) efficiently reduced proliferation of NSCLC cells in vitro and tumour growth in vivo. Finally, RNA profiling of lung epithelial cells (BEAS-2B) expressing a mutant allele of PIK3 (E545K) identified a network of transcription factors such as MYC, FOS and HMGA1, not previously recognised to be associated with aberrant PI3K signalling in lung cancer.

AB - Aberrant activation of PI3K/AKT signalling represents one of the most common molecular alterations in lung cancer, though the relative contribution of the single components of the cascade to the NSCLC development is still poorly defined. In this manuscript we have investigated the relationship between expression and genetic alterations of the components of the PI3K/AKT pathway [KRAS, the catalytic subunit of PI3K (p110α), PTEN, AKT1 and AKT2] and the activation of AKT in 107 surgically resected NSCLCs and have analyzed the existing relationships with clinico-pathologic features. Expression analysis was performed by immunohistochemistry on Tissue Micro Arrays (TMA); mutation analysis was performed by DNA sequencing; copy number variation was determined by FISH. We report that activation of PI3K/AKT pathway in Italian NSCLC patients is associated with high grade (G3-G4 compared with G1-G2; n = 83; p<0.05) and more advanced disease (TNM stage III vs. stages I and II; n = 26; p<0.05). In addition, we found that PTEN loss (41/104, 39%) and the overexpression of p110α (27/92, 29%) represent the most frequent aberration observed in NSCLCs. Less frequent molecular lesions comprised the overexpression of AKT2 (18/83, 22%) or AKT1 (17/96, 18%), and KRAS mutation (7/63, 11%). Our results indicate that, among all genes, only p110α overexpression was significantly associated to AKT activation in NSCLCs (p = 0.02). Manipulation of p110α expression in lung cancer cells carrying an active PI3K allele (NCI-H460) efficiently reduced proliferation of NSCLC cells in vitro and tumour growth in vivo. Finally, RNA profiling of lung epithelial cells (BEAS-2B) expressing a mutant allele of PIK3 (E545K) identified a network of transcription factors such as MYC, FOS and HMGA1, not previously recognised to be associated with aberrant PI3K signalling in lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84857164614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857164614&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0030427

DO - 10.1371/journal.pone.0030427

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e30427

ER -